
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
In this week’s Pointers With Portela, the 208SkinDoc reviews a patient case of topical steroid withdrawal.
In his most recent
Some of the content covered by Portela includes:
Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.






